K-V sues compounders of Makena knockoffs; Sigma-Aldrich lauds HP API sales; Marshals seize Dr. Brain drugs;

> K-V Pharmaceutical, which filed for bankruptcy after the FDA didn't stop compounding pharmacies from making cheaper versions of its premature birth prevention drug Makena, has filed suit against 40 compounding companies for infringing its rights. Story

> Fujifilm Diosynth Biotechnologies has created a partnership with Piramal Healthcare to develop and manufacture antibody drug conjugates, which are used in a few targeted drugs. Story

> A highlight of a somewhat disappointing earnings report from chemical and active pharmaceutical ingredient maker Sigma-Aldrich ($SIAL) was sales of high-potency compounds from its Verona, WI, plant, where it completed a $30 million expansion in 2010. Earnings transcript

> Prescription drug distributor McKesson Corp. ($MCK) is expanding its medical supplies business by buying PSS World Medical Inc. for about $1.46 billion. Story

> Indianapolis-based Redbird Medical has moved into the crowded contract manufacturing field with a slate of services ranging from manufacturing to supply chain management. Release

> The Maharashtra Chemist and Distributors Federation (MCDF) in India, which filed a complaint earlier about the drug storage conditions at a Cipla manufacturing facility, is asking state regulators to retest drug samples seized at the time, saying it is suspicious that essentially all of them passed even though they were found to have been held under unsuitable conditions. Story

And Finally... The FDA had U.S. Marshals seize from Confidence Inc., of Port Washington, NY, unapproved drugs, including Dr. Brain, which the company claimed could treat or cure dementia and other conditions. Release

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.